Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.Leukemia Research.  112:106770. 2021
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantationAmerican Journal of Hematology.  96:E396-E398. 2021
2021 Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United StatesCancer.  127:2966-2973. 2021
2021 Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (Leukemia, (2021), 35, 7, (2076-2085), 10.1038/s41375-021-01213-5)Leukemia.  35:2140. 2021
2021 Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRLeukemia.  35:2076-2085. 2021
2021 Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based studyAmerican Journal of Hematology.  96:E265-E268. 2021
2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantationBone Marrow Transplantation.  56:1364-1372. 2021
2021 First report of novel heterozygous WRAP53 p.Ala522Glyfs*8 mutation associated dyskeratosis congenitaBritish Journal of Haematology2021
2021 Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysisCancer2021
2021 Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia 2021
2020 Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancerBaylor University Medical Center Proceedings.  33:331-335. 2020
2020 Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow ResultsClinical Lymphoma, Myeloma and Leukemia.  20:31-38. 2020
2019 Acute promyelocytic leukemia during pregnancy: A case report and 10-year institutional review of hematologic malignancies during pregnancy 2019
2019 Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivorsLeukemia Research.  82:1-6. 2019
2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowLeukemia Research.  74:64-67. 2018
2017 Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipelineExpert Opinion on Emerging Drugs.  22:347-355. 2017
2016 Under-recognition of hemophagocytic syndrome in United States’ rural, non-teaching hospitals 2016
2016 Genomic alterations in neuroendocrine cancers of the ovaryJournal of Ovarian Research.  9. 2016
2016 Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic SyndromeClinical Lymphoma, Myeloma and Leukemia.  16:230-236. 2016
2015 How center volumes affect early outcomes in acute myeloid leukemiaClinical Lymphoma, Myeloma and Leukemia.  15:646-654. 2015
2015 Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine 2015
2015 Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesotheliomaAnnals of Thoracic Medicine.  10:289-291. 2015
2015 Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosisLeukemia Research.  39:1342-1346. 2015
2015 Influence of insurance and marital status on outcomes of adolescents and young adults with acute lymphoblastic leukemiaClinical Lymphoma, Myeloma and Leukemia.  15:364-367. 2015
2015 Population-based analysis of the clinical features of primary small cell carcinoma of the ovary 2015
2015 Male breast cancer: A 24 year experience of a tertiary care Hospital in Pakistan 2015
2014 New oral anticoagulants in patients with atrial fibrillation (1) 2014
2013 Role of genetic counselling in prenatal diagnosis of β-thalassaemia in Pakistan. 2013
2011 Early complications after biliary enteric anastomosis for benign diseases: A retrospective analysisBMC Surgery.  11. 2011
2011 Clinical applications of the pedicled anterolateral thigh flap in penile reconstruction 2011

Investigator On

  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia  awarded by National Cancer Institute/NIH/DHHS
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by CTI BIOPHARMA CORP
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ONCOIMMUNE, INC.
  • Private Grant  awarded by FORTY SEVEN, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by BLUEPRINT MEDICINES CORPORATION
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC.
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by CHIMERIX, INC.
  • Private Grant  awarded by DELTA-FLY PHARMA INC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by CONSTELLATION PHARMACEUTICALS INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by SYROS PHARMACEUTICALS INC.
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • UAB 19113: A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML  awarded by SOUTHERN RESEARCH INSTITUTE
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Aga Khan University 2012
  • Full Name

  • Omer Jamy